摘要：
目的筛选家系早发冠心病血瘀证的特异性蛋白,为今后临床早期诊断和预防疾病提供潜在生物标志物。方法通过同位素相对标记与绝对定量技术(isobaric tags for relative and absolute quanti...展开更多 目的筛选家系早发冠心病血瘀证的特异性蛋白,为今后临床早期诊断和预防疾病提供潜在生物标志物。方法通过同位素相对标记与绝对定量技术(isobaric tags for relative and absolute quantification,i TRAQ)分析家系早发冠心病血瘀证患者、家系早发冠心病非血瘀证患者及健康人的血浆蛋白表达,数据分析后得到各组间的差异蛋白表达情况,再经差异蛋白筛选标准初步得到疾病的预测蛋白,并使用Western blot验证预测蛋白。结果通过i TRAQ技术共得到差异蛋白75个,其中家系早发冠心病血瘀证组与健康对照组之间共得到32个差异蛋白,包括22个上调蛋白与10个下调蛋白,共涉及429个生物学过程,其与角质化、皮肤发展、蛋白质激活级联反应等关系最为密切;在代谢途径金黄色葡萄球菌感染、补体和凝血级联、血小板激活等KEGG通路上富集。与健康对照组相比,家系早发冠心病血瘀证组差异蛋白补体因子H(complement factor H,CFH)表达水平差异有统计学意义(P<0.01)。结论经差异蛋白筛选标准得到的CFH蛋白,可作为家系早发冠心病血瘀证早期诊断的潜在生物标志物。收起
摘要：
Simultaneous and high-performance detection of pesticides is still a considerable challenge and urgent need. Herein, a dual-emission carbon dots (CDs)-based nonenzymatic fluorescent sensing platform has been developed, which shows excellent sensitivity and selectivity in simultaneously detecting parathion-methyl (MP) and glyphosate. CDs with emissions at 440 nm (bCDs) and 660 nm (rCDs) were prepared by hydrothermal treatment of mulberry leaves and sodium hydroxide. bCDs response to hydrolyzed MP via inner filter effect, while rCDs sense glyphosate with the aid of Cu2+ by static quenching effect. Excellent linear correlations were found for MP (0.3-65.0 & mu;M) and glyphosate (1.0-110.0 & mu;M) with limits of detection at 0.14 and 0.60 & mu;M. Notably, the pre-sented dual-channel strategy was successfully applied in simultaneously detecting MP and glyphosate in food/ herbal samples with acceptable recoveries, good precision, and high selectivity. Moreover, an OR logic gate was achieved for estimating food, herbal, or environmental safety.
期刊：
Evidence-Based Complementary and Alternative Medicine,2022年2022:4692217 ISSN：1741-427X
通讯作者：
Chen, L.;Li, J.
作者机构：
[Xie, Ting; Zhang, Mengxue; Yu, Zixuan; Li, Jie; Liu, Jia; Zhang, Xiangzhuo; Jiang, Yujie; Chen, Yuxia; Zhang, Shumeng] Hunan Univ Tradit Chinese Med, Changsha 410208, Hunan, Peoples R China.;[Zhang, Mengxue] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Shanghai 200032, Peoples R China.;[Chen, Lingli] Hunan Univ Chinese Med, Hunan Prov Key Lab Pathogen Biol Based Integrated, Changsha 410208, Hunan, Peoples R China.
通讯机构：
[Li, J.; Chen, L.] H;Hunan University of Traditional Chinese Medicine, Hunan, China;Hunan Prov. Key Laboratory of Pathogenic Biology Based on Integrated Chinese and Western Medicine, Hunan, China
摘要：
This study aimed to explore the mechanism of Yangxin Tongmai decoction (YXTMD) in the treatment of coronary heart disease (CHD) with blood stasis syndrome (BSS) using network pharmacology and molecular docking, and to verify these results through clinical trials. The active compounds of YXTMD were identified using the Traditional Chinese Medicine Systems Pharmacology database, and the targets of the active compounds were predicted using the SwissTarget Prediction database. The targets of CHD and BSS were predicted using the GeneCards, OMIM, PharmGKB, TTD, and DrugBank databases. The common targets of “herb-disease-phenotype” were obtained using a Venn diagram, then used Cytoscape software 3.8.2 and its plug-in CytoNCA and STRING database to construct the “herb active compounds-common target” and protein–protein interaction networks. R language software and bioconductor plug-in were used for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. AutoDock was used for the molecular docking analysis. Finally, clinical trials were conducted to confirm the results of network pharmacology. Eighty-three active components were obtained, and the core active components were 5,7,4′-trimethoxyflavone, tetramethoxyluteolin, isosinensetin, sinensetin, and 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one. A total of 140 common targets were identified, and the core targets were EGFR, VEGFA, AKT1, STAT3, TP53, ERBB2, and PIK3CA. Biological processes identified by the GO analysis primarily involved wound healing, regulation of body fluid levels, and vascular process in circulatory system. The cellular components were primarily located in the membrane raft, membrane microdomain, and plasma membrane raft. The primary molecular functions were activity of transmembrane receptor protein kinase, transmembrane receptor protein tyrosine kinase, and protein tyrosine kinase. KEGG analysis showed that the PI3K-Akt signaling pathway was closely related to the treatment of CHD with BSS by YXTMD. Molecular docking results showed that the core active components had a good binding activity with the core targets. The clinical trial results showed that YXTMD improved the BSS scores and decreased the serum levels of total cholesterol and low-density lipoprotein cholesterol. Moreover, the levels of <i>PI3k</i> and <i>AKt</i> mRNA were upregulated and the levels of <i>GSK-3β</i> mRNA were downregulated. YXTMD has multicomponent, multitarget, and multipathway effects in the treatment of CHD with BSS, and its mechanism of action may involve activation of the PI3K-AKt signaling pathway, downregulation of GSK-3<i>β</i>, and mediation of in vivo lipid metabolism-based metabolic processes.
